1st May 2025
Ryzodeg 70/30 insulin and Freestyle Libre 2 plus continuous glucose monitoring are now available. Ryzodeg is a co-formulation of 70% degludec insulin (ultra long-acting basal insulin) and 30% aspart insulin (rapid-acting insulin) that will only be available in 3ml cartridges for NovoPens. Due to degludec insulin having a half-life of 25 hours, Ryzodeg will be a useful option for those who tend to have only one large meal per day and/or where one injection per day is desirable, and should not be administered more than twice daily. Guidance on how to use Ryzodeg can be found here.
The Freestyle Libre 2 plus is designed as a stand-alone continuous glucose monitor (CGM) and will gradually replace the Freestyle Libre 2 model. Advantages of the Freestyle Libre 2 plus system are that it is more accurate and has longer sensor wear (15 days vs 14 days) than the older Freestyle Libre 2 system with no need to change the app or reader. It will be important to switch people currently on the Freestyle Libre 2 to the Freestyle Libre 2 plus to ensure ongoing supply.
1st March 2025
People with type 2 diabetes can now be started on funded liraglutide (Victoza) and there is now dual funding of empagliflozin (Jardiance) and GLP1Ra for people with type 2 diabetes and heart failure. People already on Victoza and dulaglutide (Trulicity) can also continue their current regimen due to improved supply. Importantly, empagliflozin (Jardiance) is now funded for heart failure in addition to funding of GLP1Ra for type 2 diabetes. Therefore, people with T2D and heart failure should ideally be on funded empagliflozin under the heart failure special authority criteria and funded GLP1Ra under the diabetes special authority if the HbA1c remains above target.
The NZSSD has developed national up to date and evidence-based guidance for the management of type 2 diabetes in adults with support of the Ministry of Health. The guidance is designed as a concise pragmatic resource for all health professionals working with people with type 2 diabetes in New Zealand and will be updated as evidence and practice changes.
How to navigate the guidance documents: The management and insulin algorithms below are the overarching documents for the guidance. Clicking on the blue text will take you to that relevant section and clicking on underlined text will open up further information in a text box. Please note that currently the guidance does not cover the management of type 2 diabetes in children or other types of diabetes (including type 1 diabetes) in adults.
Please use the links below for summaries of changes in the guidance: